A5028882183- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- Uterine Myomas and Treatments
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Intestinal and Peritoneal Adhesions
- Cancer survivorship and care
- Endometriosis Research and Treatment
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Maternal Mental Health During Pregnancy and Postpartum
- Hernia repair and management
- Endometrial and Cervical Cancer Treatments
- Surgical Sutures and Adhesives
- Economic and Financial Impacts of Cancer
- Gynecological conditions and treatments
- Health and Medical Studies
- Ovarian cancer diagnosis and treatment
- MicroRNA in disease regulation
- BRCA gene mutations in cancer
- Clinical practice guidelines implementation
- Colorectal Cancer Treatments and Studies
- Medical and Health Sciences Research
- Cancer Immunotherapy and Biomarkers
University Hospital in Halle
2024-2025
Martin Luther University Halle-Wittenberg
2024-2025
University Hospital Heidelberg
2015-2024
Heidelberg University
2015-2024
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
2024
Klinik und Poliklinik für Urologie
2024
Frauenklinik Heidelberg
2014-2023
Universitäts Frauenklinik
2012-2023
European Society of Anaesthesiology
2023
Heidelberg University
2011-2022
The use of circulating tumor cells (CTC) as a prognostic marker in metastatic breast cancer (MBC) has been well established. However, their efficacy and accuracy are still under scrutiny mainly because methods enrichment identification. We hypothesized that miRNAs can predict the CTC status patients with MBC, tested for same. Furthermore, we aimed at establishing panel capable differentiating MBC cases from healthy controls.Circulating plasma CTC-positive CTC-negative controls, were profiled...
Background: Intra-abdominal adhesions arise after more than 50% of all abdominal operations and are an important source postoperative complications.They attach normally separated organs to each other can cause major problems for the affected patients by giving rise small bowel obstruction, chronic pelvic pain, dyspareunia, infertility, higher complication rates in subsequent operations.They also a frequent medicolegal conflict.Thus, every physician should be familiar with their mechanism...
Metastasis is the principal cause of high morbidity and mortality among breast cancer (BC) patients. Identification markers that can be routinely monitored to predict onset metastasis in BC patients prognosis metastatic (MBC) would increase their median survival. In this study, plasma miRNAs 40 MBC were profiled by TaqMan low density arrays with prognostic capacity identified. The candidates validated initially samples 237 subsequently 335 from an independent study cohort Sixteen established...
With growing demand for medical information and health applications in pregnancy, the potential of electronic (eHealth) mobile (mHealth) solutions clinical care is increasingly unfolding. However, we still do not know how pregnant women engage with apps, such apps impact routine care, whether benefit expectations are met. Whereas recent research has raised subject user distribution analyzed content pregnancy applications, there a significant knowledge gap regarding what like dislike about...
Progress has been made in the treatment of metastatic breast cancer recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after publication reference human genome sequence, analysis methods have improved enormously, fostering hope that biomarkers can be used individualize and offer precise based on tumor characteristics. Biomarkers at every level system (genetics, epigenetics, gene expression, micro-RNA,...
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
Abstract Purpose This study investigated the concordance of five different publicly available Large Language Models (LLM) with recommendations a multidisciplinary tumor board regarding treatment for complex breast cancer patient profiles. Methods Five LLM, including three versions ChatGPT (version 4 and 3.5, data access until September 3021 January 2022), Llama2, Bard were prompted to produce 20 LLM compared (gold standard), surgical, endocrine systemic treatment, radiotherapy, genetic...
// Irène Baccelli 1 , 2 * Albrecht Stenzinger 3 Vanessa Vogel Berit Maria Pfitzner 4 Corinna Klein Markus Wallwiener 5 Martina Scharpff Massimo Saini Tim Holland-Letz 6 Hans-Peter Sinn Andreas Schneeweiss Carsten Denkert 7 Wilko Weichert Trumpp Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany Divison of Cells Cancer, Deutsches Krebsforschungszentrum (DKFZ), Pathology, University Hospital 224, Charité...
Abstract The peritoneum plays an essential role in preventing abdominal frictions and adhesions can be utilized as a dialysis membrane. Its physiological ultrastructure, however, has not yet been studied systematically. 106 standardized peritoneal 69 omental specimens were obtained from 107 patients (0.1–60 years) undergoing surgery for disease affecting the automated quantitative histomorphometry immunohistochemistry. mesothelial cell layer morphology protein expression pattern is similar...
In metastatic breast cancer (MBC), antigen profiles of tissue and primary tumor differ in up to 20 % patients. Reassessment predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help optimize MBC treatment. While sampling is invasive often difficult repeat, circulating cell (CTC) analysis requires only a blood sample provide an easy-to-repeat, real-time “liquid biopsy” approach. The present retrospective study was conducted compare HER2 expression...
To prospectively assess circulating tumor cell (CTC) status at baseline (CTCBL) and after one cycle of a new line systemic therapy (CTC1C), changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) for their utility in predicting response, progression-free (PFS) overall survival (OS) metastatic breast cancer (MBC). was determined as negative (-) or positive (+) < 5 ≥ CTCs/7.5 ml blood using CellSearch™ (Veridex). CTCKIN categorized favorable (CTC1C-) unfavorable (CTC1C+). Tumor response be assessed...
PurposeTreatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients advanced hormone receptor–positive, HER2-negative (HR HER2–) breast cancer (BC). However, real-world data on the implementation of usage, efficacy, toxicity have not yet been reported.MethodsThe PRAEGNANT registry was used to identify HR HER2– BC (n = 1136). The use chemotherapy, ET, everolimus CDK4/6i ET analyzed first-line, second-line, third-line therapy. Progression-free survival (PFS)...